Effect of Switching From Cigarette Smoking to IQOS on Exercise Capacity
NCT ID: NCT03887117
Last Updated: 2021-12-27
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
94 participants
INTERVENTIONAL
2019-02-01
2020-03-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Mobile health technology was used in the study to explore the impact on switching from smoking to using IQOS on physical activity in daily real-world living conditions. The wearable enabled non-invasive recording of physical activity in an objective manner throughout the study. However, results collected from this device will be reported separately.
It should be noted that some study outcomes were reported graphically, rather than numerically. Consequently, these outcomes have not been included in this results disclosure.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
IQOS-1
IQOS + Exercise Training Program
Subjects randomized to IQOS use will switch to IQOS use and participate in an exercise training program.
IQOS + Exercise Training Program
Switch to IQOS use + participation in a training program
IQOS-2
IQOS without Exercise Training Program
Subjects randomized to IQOS use will switch to IQOS use, but will not participate in an exercise training program.
IQOS without Exercise Training Program
Switch to IQOS use only, without participation in a training program
Cigarette Smoking
Cigarette Smoking + Exercise Training Program
Subjects randomized to continued cigarette smoking and participation in an exercise training program.
Cigarette Smoking + Exercise Training Program
Continue to smoke cigarettes + participation in a training program
Smoking Abstinence
Smoking Abstinence + Exercise Training Program
Subjects randomized to smoking abstinence and participation in an exercise training program.
Smoking Abstinence + Exercise Training Program
Switch to smoking abstinence + participation in a training program
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
IQOS + Exercise Training Program
Switch to IQOS use + participation in a training program
IQOS without Exercise Training Program
Switch to IQOS use only, without participation in a training program
Cigarette Smoking + Exercise Training Program
Continue to smoke cigarettes + participation in a training program
Smoking Abstinence + Exercise Training Program
Switch to smoking abstinence + participation in a training program
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject has been smoking for at least three years prior to V1.
* Subject has been smoking ≥ 10 cigarettes per day over the last 12 months. Smoking status will be verified by a urinary cotinine ≥ 200 ng/mL and CO exhaled breath test \> 10 ppm both at V1 and V2.
* Subject does not plan to quit smoking within 6 months after V1.
Exclusion Criteria
* Subject performs more than 45 min of vigorous physical activity per week.
* Subject takes medication influencing blood volume such as erythropoietin, diuretics and beta blockers, or diabetic medications.
* Subject cannot participate in the study for any reason other than medical as per the Investigator's judgment (e.g. psychological and/or social reason)
* For women only: subject is pregnant (does not have negative pregnancy tests at V1 and at V2) or is breastfeeding.
* For women of childbearing potential : female subject who does not agree to using an acceptable method of effective contraception during the entire study.
* Subject has a BMI \< 18.5 kg/m2 or BMI ≥ 30 kg/m2.
* Subject has a positive urine drug screen.
* Subject has been previously screened for this study.
* Subject, or one of their family members (e.g., spouse, parent, sibling or child), is a current or former employee of the tobacco industry.
* Subject, or one of their family members (e.g. spouse, parent, sibling or child), is an employee of the investigational site or any other parties involved in the study.
* Subject is legally incompetent, or physically or mentally incapable of giving consent (e.g., emergency situation, under guardianship, prisoners, or subjects who are involuntarily incarcerated).
21 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Philip Morris Products S.A.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Armin Schultz, MD
Role: PRINCIPAL_INVESTIGATOR
CRS Clinical Research Services Mannheim GmbH
Christelle Haziza, PhD
Role: STUDY_CHAIR
Philip Morris Products S.A.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CRS Clinical Research Services Mannheim GmbH
Mannheim, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
P1-EXC-01-EU
Identifier Type: -
Identifier Source: org_study_id